Anemia of the Chronic Kidney Disease: A Comparision Between Oral and Intravenous Iron Therapy Combined with Erythropoietin
Main Article Content
Abstract
Background: Anemia is a common and significant complication in chronic kidney disease (CKD), largely due to iron deficiency and reduced erythropoietin production. This study aimed to compare the efficacy of oral versus intravenous iron supplementation, each combined with subcutaneous recombinant human erythropoietin (rHuEPO), in improving iron status and anemia in patients with chronic renal failure (CRF).
Methods: A total of 8 patients of CRF were included based on inclusion and exclusion criteria and divided into 2 groups. Group A received oral ferrous sulfate with subcutaneous (rHuEPO) and Group-B on intravenous Iran Dextran along with subcutaneous (rHuEPO). Hemoglobin and transferrin saturation (TSAT) were measured at baseline and after six months. Gender distribution was comparable in both groups.
Results: Both groups showed significant increase in hemoglobin and TSAT levels over six months (P=0.001), However, the increase was significantly higher in Group B. At six months, mean TSAT was 39.80±1.05% in Group B versus 26.96±0.95% in Group A (p=0.001), indicating superior efficacy of IV iron dextran in repleting iron stores.
Conclusion: IV Iron dextran, when combined with rHuEPO, is more effective than oral iron in improving anemia and iron status in CRF patients.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Executive Summary. American Journal of Kidney Diseases. 2006;47(3). https://pubmed.ncbi.nlm.nih.gov/16678659/
3. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)z. Kidney Int 2006;67(6):2089–100.
4. Besarab A, Levin A. Defining a renal anemia management period. American Journal of Kidney Diseases.2000;36(6). https://pubmed.ncbi.nlm.nih.gov/11118154/
5. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501–10.
6. Gaweda AE. Markers of Iron Status in Chronic Kidney Disease Diagnosing Iron Deficiency. Hemodial Int. 2017;21(1):S21. https://pmc.ncbi.nlm.nih.gov/articles/PMC6247786/
7. Huebers HA, Finch CA. The physiology of transferrin and transferrin receptors.1987;67(2):520–82.
8. Kamal A. estimation of blood urea (bun) and serum creatinine level in patients of renal disorder. 2014;4. http://www.cibtech.org/jls.htm
9. Gaitonde DY, Cook DL, Rivera IM, Eisenhower DD. Chronic Kidney Disease: Detection and Evaluation. Am Fam Physician. 2017;96(12):776–83.
10. Toblli JE, Di Gennaro F. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: Effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. PLoS One. 2015;10(4). https://pubmed.ncbi.nlm.nih.gov/25928811/
11. Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Lüscher T, et al. The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study. Eur J Heart Fail. 2015;17(3):329–39.
12. Ratna palit dakrskrsjp. iron status in anemia of chronic kidney disease (ckd) stage-v and its improvement with intravenous iron supplementation. international journal of pharma and bioscience. 2014 Jul;5(3):91–7.
13. Jenq CC, Tian YC, Wu HH, Hsu PY, Huang JY, Chen YC, et al. Effectiveness of oral and intravenous iron therapy in haemodialysis patients. Int J Clin Pract. 2007 ;62(3):416–22.
14. Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation. 2015;30(4): 645–52